Funding
Open Access funding enabled and organized by Projekt DEAL. Under the terms of the glucagon/GLP-1 licensing agreement, Boehringer Ingelheim funds all research, development and commercialisation activities. Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany) funded the study and had a role in study design, data collection, data analysis and data interpretation and provided support for editorial aspects of this report.